AON-MG23

AON-MG23 is a preclinical-stage small molecule dual inhibitor targeting Anoctamin 1 (ANO1) and the Epidermal Growth Factor Receptor (EGFR). Developed by the South Korean biotechnology company Astrion, the compound is designed to address solid tumors where both ANO1 and EGFR are overexpressed or play synergistic roles in tumor progression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and glioblastoma (GBM). ANO1 is a calcium-activated chloride channel often amplified in various cancers, where it promotes cell proliferation, migration, and survival, while EGFR is a well-established oncogenic driver. By simultaneously inhibiting both targets, AON-MG23 aims to overcome resistance mechanisms associated with single-agent EGFR inhibitors and provide a more potent anti-tumor effect. The drug is currently in non-clinical development, with IND filing targets ranging from late 2026 to 2028 depending on the indication.

Other names

AON-MG23AON-MG-23AON-MG 23